Neal Lakritz, MD
Addiction Medicine · Enfield, CTNPI 1780640383
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $853 and has fallen 85.5% since, to $123 in 2025. Among addiction medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$550
- GSK$272
- Novo Nordisk$217
- AstraZeneca$194
- Lilly USA, LLC$176
- AbbVie$154
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,651100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 34 | $550 |
| GSK | 19 | $272 |
| Novo Nordisk | 12 | $217 |
| AstraZeneca | 12 | $194 |
| Lilly USA, LLC | 8 | $176 |
| AbbVie(2 entities) | 7 | $154 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 2 | $123 |
| Astellas Pharma US Inc | 4 | $82 |
| Novartis | 5 | $82 |
| Abbott | 4 | $76 |
| Exact Sciences | 3 | $56 |
| Boehringer Ingelheim | 3 | $54 |
| Almatica Pharma LLC | 2 | $51 |
| Dexcom, Inc. | 2 | $41 |
| Corium, LLC | 3 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $21 |
| Lifescan, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Covis Pharma GmbH | 1 | $18 |
| Amgen | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$125
How this compares
$2,651 in reported general payments places this provider in the 90th percentile of 28 addiction medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 118 | $118,983 |
| OzempicSemaglutide | 62 | $76,332 |
| JardianceEmpagliflozin | 61 | $61,927 |
| FarxigaDapagliflozin Propanediol | 33 | $43,333 |
| TrulicityDulaglutide | 27 | $40,099 |
| JanuviaSitagliptin Phosphate | 17 | $23,220 |
| ProliaDenosumab | 13 | $22,672 |
| OxycontinOxycodone Hcl | 26 | $16,195 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $13,145 |
| XareltoRivaroxaban | 14 | $11,791 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 104 | $10,688 |
| Atorvastatin Calcium | 585 | $8,607 |
| MyrbetriqMirabegron | 14 | $8,197 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 14 | $7,769 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $7,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $550 | $118,983118 claims |
| Novo NordiskOzempic | $217 | $76,33262 claims |
| Boehringer IngelheimJardiance | $54 | $61,92761 claims |
| AstraZenecaFarxiga | $194 | $43,33333 claims |
| Lilly USA, LLCTrulicity | $176 | $40,09927 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $272 | $26,14545 claims |
| AmgenProlia | $18 | $22,67213 claims |
| Astellas Pharma US IncMyrbetriq | $82 | $8,19714 claims |
| AbbVieSynthroid | $154 | $2,06357 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 28 addiction medicine providers in Connecticut.
Other addiction medicine in Enfield
- Robin DeutschEnfield$324
- Jenna ButnerNew Haven$27K
- Ayaz MadraswallaPutnam$14K
- Mahboob AslamRocky Hill$2K
- Thomas DefantiNorth Stonington$1K
- Edith HerganRocky Hill$1K
- John AntonucciNewington$1K
- Brian KarsifNew Haven$528
- Jay BensonRocky Hill$393
- Sijie WangFarmington$387
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.